Difference between revisions of "Resource:C1141bae-df2e-4f56-85aa-7e26dc38197b"
From The Embassy of Good Science
(Created page with "{{Resource |Resource Type=Cases |Title=Clinical Trials and Drug Promotion: Selective Reporting of Study 329 |Is About=This article describes the ethical issues regarding the S...") |
|||
| Line 6: | Line 6: | ||
}} | }} | ||
{{Link | {{Link | ||
| − | |Has Link=https://www.researchgate.net/publication/ | + | |Has Link=https://www.researchgate.net/publication/228649054_Clinical_Trials_and_Drug_Promotion_Selective_Reporting_of_Study_329 |
}} | }} | ||
{{Related To}} | {{Related To}} | ||
{{Tags | {{Tags | ||
| − | |Involves= | + | |Involves=Jon Jureidini; Leemon McHenry; Peter R Mansfield |
| − | |Has Timepoint= | + | |Has Timepoint=2008 |
|Has Virtue And Value=Honesty; Transparency | |Has Virtue And Value=Honesty; Transparency | ||
}} | }} | ||
Revision as of 12:56, 2 September 2021
ResourcesCases
Clinical Trials and Drug Promotion: Selective Reporting of Study 329
What is this about?
This article describes the ethical issues regarding the Study 329. The Study wanted to determine the efficacy and safety of imipramine and paroxetine in the treatment of adolescents with major depression. However, it did not comply with the study protocol and ignored important safety problems, which led to some harmful effects.
